Certolizumab pegol for the treatment of Crohn's disease.

abstract：Aims:Gastric cancer (GC) is the third leading cause of cancer death worldwide, but the burden of disease is not distributed evenly. GC screening routinely occurs in some high-incidence regions/countries and is generally cost-effective, which is attributed largely to the associated GC mortality reduction. In regions of ...

journal_title：Therapeutic advances in gastroenterology

authors： Canakis A,Pani E,Saumoy M,Shah SC

更新日期：2020-07-16 00:00:00

abstract：:Gut microbiota is a compilation of microorganisms dwelling in the entire mammalian gastrointestinal tract. They display a symbiotic relationship with the host contributing to its intestinal health and disease. Even a slight fluctuation in this equipoise may be deleterious to the host, leading to many pathological cond...

journal_title：Therapeutic advances in gastroenterology

authors： Bien J,Palagani V,Bozko P

更新日期：2013-01-01 00:00:00

abstract：:Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract cancer (BTC). Recent largescale molecular profiling studies have not only highlighted genomic differences characterizing tumors of the intrahe...

journal_title：Therapeutic advances in gastroenterology

authors： Lee H,Ross JS

更新日期：2017-06-01 00:00:00

abstract：:Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremend...

journal_title：Therapeutic advances in gastroenterology

authors： Khanna S,Pardi DS

更新日期：2014-03-01 00:00:00

abstract：:The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...

journal_title：Therapeutic advances in gastroenterology

authors： Olsen SK,Brown RS,Siegel AB

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...

journal_title：Therapeutic advances in gastroenterology

authors： Bhat YM,Furth EE,Brensinger CM,Ginsberg GG

更新日期：2009-11-01 00:00:00

abstract：:The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...

journal_title：Therapeutic advances in gastroenterology

authors： Oke S,Martin A

更新日期：2017-05-01 00:00:00

abstract：:Severe acute pancreatitis (SAP) is a critical abdominal disease associated with high death rates. A systemic inflammatory response promotes disease progression, resulting in multiple organ dysfunction. The functions of neutrophils in the pathology of SAP have been presumed traditionally to be activation of chemokine a...

journal_title：Therapeutic advances in gastroenterology

authors： Hu J,Kang H,Chen H,Yao J,Yi X,Tang W,Wan M

更新日期：2020-11-24 00:00:00

abstract：BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...

journal_title：Therapeutic advances in gastroenterology

authors： Cash BD,Pimentel M,Rao SSC,Weinstock L,Chang L,Heimanson Z,Lembo A

更新日期：2017-09-01 00:00:00

abstract：:Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...

journal_title：Therapeutic advances in gastroenterology

authors： Panaccione R,Ghosh S

更新日期：2010-05-01 00:00:00

abstract：Introduction:Hepatocholangiocarcinoma (HCC-ICC) is a rare tumor presenting the histologic characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). As there is no consensus on it management, the therapeutic strategy rests on the specific treatments for HCC or ICC. Programmed cell...

journal_title：Therapeutic advances in gastroenterology

authors： Saint A,Benchetrit M,Novellas S,Ouzan D,Falk AT,Leysalle A,Barriere J

更新日期：2020-06-20 00:00:00

abstract：Background:Pharmacotherapy, including prokinetics and proton pump inhibitors for functional dyspepsia (FD) have limited effectiveness, and their safety has been recently questioned. Chinese herbal medicine (CHM) could be considered as an alternative. A systematic review (SR) of SRs was performed to evaluate the potenti...

journal_title：Therapeutic advances in gastroenterology

authors： Chu MHK,Wu IXY,Ho RST,Wong CHL,Zhang AL,Zhang Y,Wu JCY,Chung VCH

更新日期：2018-07-16 00:00:00

abstract：:Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce t...

journal_title：Therapeutic advances in gastroenterology

authors： Vermeire S,Gils A,Accossato P,Lula S,Marren A

更新日期：2018-01-21 00:00:00

abstract：:Capsule endoscopy for the colon was introduced to allow an alternative screening method to the invasive classic colonoscopy. The results of initial studies have shown inferior detection rates of colonic polyps by the colon capsule. In this paper we aim to review and summarize the recent advances in wireless capsule en...

journal_title：Therapeutic advances in gastroenterology

authors： Adler SN,Metzger YC

更新日期：2011-07-01 00:00:00

abstract：:Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...

journal_title：Therapeutic advances in gastroenterology

authors： Kelesidis T,Pothoulakis C

更新日期：2012-03-01 00:00:00

abstract：:Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutati...

journal_title：Therapeutic advances in gastroenterology

authors： Patel MR,Eppolito AL,Willingham FF

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...

journal_title：Therapeutic advances in gastroenterology

authors： Malespin M,Benyashvili T,Uprichard SL,Perelson AS,Dahari H,Cotler SJ

更新日期：2017-01-01 00:00:00

abstract：:The incidence and prevalence of ulcerative colitis (UC) has been reported to be rising in newly industrialised regions, such as Latin America. Here, we review data from published studies reporting demographics and clinical aspects of UC in Latin America to further understand epidemiology and disease burden. The incide...

journal_title：Therapeutic advances in gastroenterology

authors： Kotze PG,Steinwurz F,Francisconi C,Zaltman C,Pinheiro M,Salese L,Ponce de Leon D

更新日期：2020-07-09 00:00:00

abstract：:Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...

journal_title：Therapeutic advances in gastroenterology

authors： Kim HY,Park JW

更新日期：2017-10-01 00:00:00

abstract：:Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease rangi...

journal_title：Therapeutic advances in gastroenterology

authors： Kneeman JM,Misdraji J,Corey KE

更新日期：2012-05-01 00:00:00

abstract：Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...

journal_title：Therapeutic advances in gastroenterology

authors： Chen B,Gao X,Zhong J,Ren J,Zhu X,Liu Z,Wu K,Kalabic J,Yu Z,Huang B,Kwatra N,Doan T,Robinson AM,Chen MH

更新日期：2020-07-16 00:00:00

abstract：BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...

journal_title：Therapeutic advances in gastroenterology

authors： Cereatti F,Fiocca F,Dumont JL,Ceci V,Vergeau BM,Tuszynski T,Meduri B,Donatelli G

更新日期：2016-03-01 00:00:00

abstract：:Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...

journal_title：Therapeutic advances in gastroenterology

authors： Lam BP,Jeffers T,Younoszai Z,Fazel Y,Younossi ZM

更新日期：2015-09-01 00:00:00

abstract：:Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...

journal_title：Therapeutic advances in gastroenterology

authors： Sanger GJ,Chang L,Bountra C,Houghton LA

更新日期：2010-09-01 00:00:00

abstract：:In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

journal_title：Therapeutic advances in gastroenterology

authors： Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

更新日期：2019-06-14 00:00:00

abstract：Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...

journal_title：Therapeutic advances in gastroenterology

authors： Mori H,Suzuki H,Omata F,Masaoka T,Asaoka D,Kawakami K,Mizuno S,Kurihara N,Nagahara A,Sakaki N,Ito M,Kawamura Y,Suzuki M,Shimada Y,Sasaki H,Matsuhisa T,Torii A,Nishizawa T,Mine T,Ohkusa T,Kawai T,Tokunaga K,Tak

更新日期：2019-07-04 00:00:00

abstract：Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...

journal_title：Therapeutic advances in gastroenterology

authors： van Rossen TM,van Dijk LJ,Heymans MW,Dekkers OM,Vandenbroucke-Grauls CMJE,van Beurden YH

更新日期：2021-01-09 00:00:00

abstract：:The human gastrointestinal tract comprises a series of complex and dynamic organs ranging from the stomach to the distal colon, which harbor immense microbial assemblages that are known to be vital for human health. Until recently, most of the details concerning our gut microbiota remained obscure. Over the past sever...

journal_title：Therapeutic advances in gastroenterology

authors： Kovatcheva-Datchary P,Zoetendal EG,Venema K,de Vos WM,Smidt H

更新日期：2009-07-01 00:00:00

abstract：Background:In patients with a large, unresectable hepatocellular carcinoma (HCC), the primary recommendation is for transarterial chemoembolization (TACE) but used alone TACE is not typically curative. Combinations of TACE followed in a delayed fashion by single-applicator thermal ablation have also been suboptimal. As...

journal_title：Therapeutic advances in gastroenterology

authors： Zhang TQ,Huang ZM,Shen JX,Chen GQ,Shen LJ,Ai F,Gu YK,Yao W,Zhang YY,Guo RP,Chen MS,Huang JH

更新日期：2019-08-21 00:00:00

abstract：:Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...

journal_title：Therapeutic advances in gastroenterology

authors： Vilaseca M,Guixé-Muntet S,Fernández-Iglesias A,Gracia-Sancho J

更新日期：2018-11-25 00:00:00